Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). (Q50627188)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 November 2008

Language	Label	Description	Also known as
English	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).	scientific article published on 26 November 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

0 references

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

0 references

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

2

object named as

Adrian Covic

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

Raymond Vanholder

5

object named as

Raymond Vanholder

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

Andrzej Więcek

4

object named as

Andrzej Wiecek

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

Kai-Uwe Eckardt

3

object named as

Kai-Uwe Eckardt

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

ERA-EDTA ERBP Advisory Board

6

object named as

ERA-EDTA ERBP Advisory Board

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

Francesco Locatelli

1

object named as

Francesco Locatelli

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

language of work or name

0 references

publication date

26 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

24

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

348-354

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

The burden of kidney disease: improving global outcomes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Hemoglobin variability and mortality in ESRD.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN653

21 January 2018

Identifiers

10.1093/NDT/GFN653

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/19037082

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50627188&oldid=2165423308"